NIH-Funded Trial Studies if Wearables Can Reduce the Need for Continuous Blood Thinners for Patients with Atrial Fibrillation | Newswise
Newswise — CHICAGO — March 27, 2025 — Atrial fibrillation (AFib) is the most common type of heart arrhythmia impacting more than 5 million people in the United States, a number that is anticipated to reach 12.1 million by 2030. The heart rhythm condition is characterized by fast and irregular heartbeats from the upper chambers of the heart. People with AFib are at increased risk of stroke, heart failure, dementia, and premature death. To reduce risk of stroke from blood clots, many patients with AFib are treated with life-long oral anticoagulation therapy, yet blood thinning medications come with their own risks, including excessive bleeding. Individuals with AFib may now be eligible to enroll in a clinical trial that will study if wearable technology can help reduce the reliance on these medications.
“For both patients and physicians, it can be challenging to balance the risk and benefits of continuous anticoagulation therapy,” said Rod Passman, MD, MSCE cardiac electrophysiologist at Northwestern Medicine Bluhm Cardiovascular Institute and director of the Center for Arrhythmia Research at Northwestern University Feinberg School of Medicine. “Currently, standard of care for AFib leaves many patients on blood thinners for the rest of their lives even if they experience very infrequent arrhythmias either on their own or as the result of medications or ablation treatment.”
The seven-year trial will recruit participants at more than 80 sites nationwide, randomizing them to either receive the current standard of care of continuous blood thinners or the “pill-in-pocket” treatment directed by a study app on Apple Watch. The trial will also examine whether this new approach can reduce major bleeding events compared to continuous therapy.
Dr. Passman is leading a clinical trial that, if successful, could potentially provide a more personalized approach to preventing AFib-related stroke. The Rhythm Evaluation for AntiCoagulaTion (REACT-AF) trial will monitor a participant’s AFib episodes to attempt to reduce patients’ continuous and lifelong reliance on blood-thinning medication. A collaboration between Northwestern Medicine and the American Heart Association, the study is funded by a multi-million-dollar grant awarded to Northwestern University and Johns Hopkins University from the National Heart, Lung, and Blood Institute.
“We know that risk of stroke is greatest in the weeks following an episode of AFib then returns to a low level, which suggests the potential for anticoagulant therapy only as needed rather than every day of the year,” says Dr. Passman, the principal investigator for REACT-AF. “However, many patients have no symptoms of AFib, so treating in the moment is challenging. That’s where wearable technology comes in.”
The trial will use a custom study app on Apple Watch that utilizes its powerful heart health features to monitor heart activity and notify patients when they’re entering an episode. When alerted to an episode, participants will start blood-thinning medications only for a few weeks when they are considered at highest risk for stroke.
“If we can show this ‘pill-in-pocket’ strategy is equally protective against stroke and also reduces bleeding caused by these blood thinners, that could potentially save lives, reduce cost, improve quality of life and fundamentally change the standard of care for millions of patients living with AFib,” said Dr. Passman, who for ten years has studied solutions to end the standard “one-size-fits-all” practice of prescribing lifelong blood thinners to everyone with AFib.
To participate in the clinical trial, individuals must have an iPhone. Apple Watch devices are provided to participants through a contribution from Apple.
“This is an exciting opportunity to better understand how this technology can help us better personalize patient care,” said Dr. Passman. “Why should patients expose themselves to the risk and cost of these drugs when they may not be benefiting?”
Individuals interested in enrolling in the study should visit ClinicalTrials.gov to review inclusion criteria and find a trial site near them.
Northwestern is the lead study site. Partnering institutions include Johns Hopkins, Stanford University and University of California at San Francisco. REACT-AF is funded by grant number 1U24HL165066-01; ClinicalTrials.gov number, NCT05836987.
For information on the Bluhm Cardiovascular Institute’s Center for Heart Rhythm Disorders or to find other cardiovascular clinical trials, visit heart.nm.org. To learn more about Northwestern Medicine, visit news.nm.org.
About Bluhm Cardiovascular Institute
Bluhm Cardiovascular Institute is an innovative powerhouse in developing the latest, safest advances in cardiovascular care. Anchored in downtown Chicago, it has expanded and integrated across the Northwestern Medicine health system, bringing advanced cardiovascular services close to where patients live and work. Consistently recognized as one of the top cardiology and cardiac surgery programs in the country, Bluhm Cardiovascular Institute at Northwestern Memorial Hospital is ranked seventh in the country by U.S. News & World Report in the annual “America’s Best Hospitals” rankings.
For more information about Northwestern Medicine’s top ranked cardiovascular care, go to nm.org/heart or call (312) NM-HEART. For more information about Northwestern Medicine, visit https://news.nm.org/.
